Shanghai, China - In May 2023, Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort^® MedBot^®) jointly set up a joint venture Shanghai Intbot Robotics Co., Ltd. (MicroPort^® Intbot^TM) together with Biobot Surgical Pte. Ltd. from Singapore. Its product Mona Lisa prostate puncture robot positioning system (Mona Lisa) was granted a marketing registration certificate by the National Medical Products Administration (NMPA) as the first prostate puncture robot licensed in the field of urology in China. The product brings changes to the traditional manual puncture mode to further promote clinical precision puncture with an intelligent navigation and positioning system, marking a leapfrog innovation and progress in prostate puncture biopsy in China, filling a gap in the domestic market and providing more medical options and creating better conditions for prostate biopsy puncture patients.

Mona Lisa is an innovative robot from the MicroPort^® MedBot^® in the track of percutaneous puncture, allowing surgeons to perform biopsy sampling more accurately and easily. By following various operations, such as intelligent planning, accurate positioning, precise compensation, it reduces the complexity of puncture, improves the accuracy of puncture, optimizes the positive detection rate of patients, cuts down missing and misdiagnosis rate, alleviates the suffering, and ultimately benefits patients.

Preoperatively, surgeons can plan and make interactive adjustment of the procedure via intelligent software; intraoperatively, powerful elastic MRI-ultrasound fusion algorithms guide surgeons in real time to easily, accurately sample the target, whether it is located in the apical, basal or peripheral zones of the prostate. The innovative trans-perineal two-point approach minimizes the disturbance of the pubic arch, reduces patient incision, and ensures complete prostate coverage; postoperatively, Mona Lisa generates a full report containing 3D images and clinical data.

The clinical registration and test results of Mona Lisa show that robot positioning puncture can improve the positive detection rate of patients, and assist clinicians to make punctures more accurately, efficiently. As there is no robot-assisted prostate puncture product available in China, the launch of Mona Lisa will fill the gap in this technology area.

Mr. Hongjun He, General Manager of Shanghai Intbot Robotics Co., Ltd., said that prostate puncture biopsy has long been the gold standard for diagnosing prostate cancer, and Mona Lisa can improve the positive detection rate of patients and assist clinicians in making puncture more accurate, efficient. With the clinical characteristics of high precision and micro-invasive, it alleviates the suffering of patients, marking the way to intelligent, precise prostate biopsy in China, while reducing the manual error and leakage rate, playing a driving role in the progress of the prostate diagnosis field. We will further develop the technology in the future with focus on the first-line clinical needs, while promoting the combination of puncture positioning system and multi-module ablation energy platform to advance the integration of treatment for the benefit of more patients.

Mr. Yu Liu, Executive Group Vice President and Chief Commercial Officer of MicroPort^® MedBot^® said that the approval by the NMPA for Mona Lisa prostate puncture robot positioning system represents a major step forward for MicroPort^® MedBot^® in the field of percutaneous puncture, providing a prerequisite for future clinically validated procedures and universal access to more patients. It provides a solid foundation for follow-up treatment options through early screening. In the future, we will build an integrated platform for diagnosis and treatment through continuous clinical application and medical-industrial cooperation, so as to benefit doctors and patients, and devote ourselves to "Making Surgery Easier, Safer and Less Invasive".